Tremfya vs Entyvio for Crohn's Disease: How They Compare

Tremfya and Entyvio are two non-anti-TNF biologics for moderate-to-severe Crohn's disease, and patients often compare them when prioritizing safety or looking for alternatives to systemic TNF blockade. Tremfya is an IL-23 p19-selective biologic with strong endoscopic data from the GALAXI and GRAVITI trials. Entyvio is gut-selective and acts almost exclusively on the intestines. Both offer meaningful safety advantages over anti-TNFs, but they work through very different mechanisms. This guide walks through the tremfya vs entyvio crohn's comparison.

IL-23 vs Gut-Selective Mechanism

Tremfya (guselkumab) binds the p19 subunit of interleukin-23, blocking a cytokine that drives the Th17 inflammatory pathway in Crohn's. Its immune effects are systemic but narrower than anti-TNF or IL-12/23 blockade, which is why its safety profile tends to be cleaner. Entyvio (vedolizumab) binds the alpha-4-beta-7 integrin, found almost exclusively on gut-homing lymphocytes. By blocking these immune cells from entering inflamed intestinal tissue, Entyvio quiets gut inflammation without meaningfully suppressing systemic immunity. The guselkumab vs vedolizumab distinction matters because mechanism shapes how each drug performs in different patient populations and affects their long-term safety profiles.

Efficacy in Crohn's

Tremfya's Crohn's data comes from GALAXI 1, GALAXI 2, and GALAXI 3, plus the GRAVITI subcutaneous induction trial. GALAXI showed strong clinical remission and endoscopic response rates in biologic-naive and biologic-experienced patients, with superiority over ustekinumab on endoscopic endpoints. Entyvio's Crohn's efficacy rests on GEMINI 2 and GEMINI 3, showing modest early response compared with placebo with improved outcomes over maintenance. No head-to-head trial has directly compared Tremfya with Entyvio in Crohn's. Indirect comparisons suggest Tremfya produces higher clinical remission rates and stronger endoscopic outcomes, while Entyvio delivers durable maintenance in patients who achieve response. For biologic-naive patients, both drugs are reasonable options with different efficacy profiles.

Onset of Action

Tremfya produces clinically meaningful response by week 12 in most Crohn's patients, with some benefit evident as early as week 4. Entyvio's onset is notably slower, with the label instructing clinicians to wait until week 14 before deciding whether the drug is working. Some patients continue to improve through week 26. For Crohn's patients with active symptoms who cannot tolerate a long ramp-up, Tremfya's faster onset is an advantage. For patients in less acute states or those prioritizing the narrowest systemic immune footprint, Entyvio's slower onset is generally manageable with supportive care.

Safety and Infection Risk

Both drugs have favorable safety profiles relative to anti-TNFs, but the risk signals differ. Entyvio's gut-selective action produces very low rates of systemic infection, and its long-term safety data is among the cleanest of any IBD biologic for non-GI infections. A 2024 Swedish registry study flagged a higher rate of serious gastrointestinal infections on vedolizumab compared with anti-TNFs, though overall systemic infection rates were lower. Tremfya's safety profile in Crohn's and its broader psoriasis experience has been favorable. For tremfya vs entyvio side effects, injection-site and infusion-related reactions are mild for both drugs. Both carry boxed warnings related to serious infections and both require TB and hepatitis B screening before starting.

Administration and Dosing

Tremfya offers dual induction pathways for Crohn's. Patients can choose IV induction (200 mg at weeks 0, 4, and 8) or fully subcutaneous induction (400 mg at weeks 0, 4, and 8). Maintenance is 100 mg SC every 8 weeks or 200 mg SC every 4 weeks. Entyvio starts with three 300 mg IV infusions at weeks 0, 2, and 6, followed by maintenance every 8 weeks. After IV induction, Entyvio patients who respond by week 6 can switch to a 108 mg subcutaneous pen every 2 weeks, according to Takeda's dosing information. For Crohn's patients who want to avoid infusion centers entirely, Tremfya's SC induction option is a meaningful practical advantage over Entyvio's IV-required induction. For long-term maintenance, both drugs offer SC options, though Tremfya's every-8-week dosing is less frequent than Entyvio's every-2-weeks SC maintenance.

Anti-TNF Experienced Patients

For Crohn's patients who have failed an anti-TNF, GALAXI included biologic-experienced patients and showed Tremfya's efficacy in this population. Entyvio has anti-TNF experienced data as well, though response rates in this setting are lower than in biologic-naive cohorts. Real-world cohorts suggest that switching from an anti-TNF to either Tremfya or Entyvio delivers better outcomes than cycling within the anti-TNF class, and the mechanism change is typically the key driver. For patients who have cycled through one anti-TNF and are choosing between Tremfya and Entyvio, trial data tends to favor Tremfya on efficacy while Entyvio offers the narrowest systemic safety profile.

Choosing With Your GI

For a Crohn's patient deciding between Tremfya and Entyvio, both drugs offer meaningful advantages over anti-TNFs. Tremfya tends to win on speed of onset, clinical remission rates, and unique SC induction flexibility. Entyvio tends to win on the narrowest systemic safety footprint and durable maintenance in patients who achieve response. Your GI will weigh disease severity, prior biologic exposure, comorbidities, and insurance coverage. Before starting either drug, ask how response will be measured after induction, what to do if symptoms persist, and whether therapeutic drug monitoring will be part of your plan. A log of stool frequency, urgency, abdominal pain, and any new symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.